NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHLBI E-035-2022-0-CA-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) CA National Stage 3243219 Pending
NCI E-237-2017-2-CR-03 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR DIV 2024-0303 Pending
NCI E-237-2017-2-CR-02 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR DIV 2024-0302 Pending
NCI E-237-2017-2-CR-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR DIV 2024-0301 Abandoned
NCATS E-022-2022-0-NL-01 METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA
FROM BIOLOGICAL ASSAYS 		NL EP 22854698.2 Issued
NCATS E-022-2022-0-DE-01 METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA
FROM BIOLOGICAL ASSAYS 		DE EP 22854698.2 Issued
NCATS E-022-2022-0-DK-01 METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA
FROM BIOLOGICAL ASSAYS 		DK EP 22854698.2 Issued
NCATS E-022-2022-0-FR-01 METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA
FROM BIOLOGICAL ASSAYS 		FR EP 22854698.2 Issued
NCATS E-022-2022-0-CH-01 METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA
FROM BIOLOGICAL ASSAYS 		CH EP 22854698.2 Issued
NCATS E-022-2022-0-EP-01 METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA
FROM BIOLOGICAL ASSAYS 		EP National Stage 22854698.2 Issued
NIDDK E-085-2022-0-EP-01 NEXT GENERATION TRANSPOSOSOMES EP National Stage 22854444.1 Pending
NCI E-075-2024-0-US-01 OXYNITIDINE DERIVATIVES USEFUL AS TYROSYL-DNA PHOSPHODIESTERASE INHIBITORS AND RADIOSENSITIZERS US 63/674,198 Expired
NCI E-161-2024-0-US-01 T CELL RECEPTORS AGAINST RAS WITH G12D, G12V, G13D OR Q61R MUTATION US 63/673,840 Expired
NCI E-056-2023-0-PCT-01 IDENTIFICATION OF NOVEL SEQUENCES OF THE ERVMER34-1 HUMAN ENDOGENOUS RETROVIRAL SEQUENCE FAMILY, AND MODIFICATION OF THOSE SEQUENCES FOR A MORE EFFECTIVE ANTI-CANCER VACCINE AND OTHER POTENTIAL ANTI-CANCER THERAPIES PCT PCT PCT/US2024/039057 Expired
NHLBI E-035-2022-0-IL-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) IL National Stage 314428 Pending
NIAID E-165-2023-0-PC-02 BISPECIFIC ANTIBODIES THAT BROADLY TARGET CORONAVIRUSES PCT PCT PCT/US2024/038583 Expired
NCI E-202-2023-0-PC-01 KINASE INHIBITORS PCT PCT PCT/US2024/038376 Expired
NIDDK E-162-2023-0-PC-01 5-HT2B SEROTONIN RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF PCT PCT COMB PCT/US2024/038286 Pending
NHLBI E-342-2013-0-US-02 Human IPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings US CON 18/775,257 Pending
NHLBI E-144-2021-0-EP-01 Guidewire for Electrosurgical Tissue Laceration EP National Stage 23737777.5 Pending
NCI E-162-2024-0-US-01 Reverse Thiazine Kinase Inhibitors US 63/672,577 Expired
NIAID E-067-2024-0-US-01 COMPOSITIONS AND METHODS FOR DETECTING LYMPHATIC FILARIASIS US 63/672,667 Expired
NIAAA E-189-2021-0-IL-01 CANNABINOID RECEPTOR MODULATING COMPOUNDS IL National Stage 314385 Abandoned
NCI E-045-2022-0-US-02 METHOD OF HUMAN LEUKOCYTE ANTIGEN LOSS OF HETEROZYGOSITY DETECTION IN LIQUID BIOPSIES US National Stage 18/729,138 Pending
NCI E-193-2017-0-US-04 Ultrasound Sensitive Peptide Particles For Spatially Resolved Molecule Delivery US DIV 18/771,481 Pending
NCI E-133-2016-0-JP-13 FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME JP DIV 2024-112931 Pending
NIAID E-095-2019-0-US-02 HIV RNA VACCINES US DIV 18/771,978 Pending
NCI E-125-2023-0-PC-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS PCT PCT PCT/US2024/037349 Expired
NEI E-212-2015-0-US-02 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS US CON 18/769,320 Pending
NCI E-188-2023-0-PC-01 HUMANIZED 40H3 ANTIBODY PCT PCT PCT/US2024/037091 Expired
NCI E-051-2022-0-US-02 METHODS OF PREDICTING PATIENT TREATMENT RESPONSE AND RESISTANCE VIA SINGLE-CELL TRANSCRIPTOMICS OF THEIR TUMORS US National Stage 18/727,094 Pending
NCI E-184-2009-0-US-05 Combination Immunotherapy Compositions Against Cancer and Methods US CON 18/764,645 Pending
NHLBI E-144-2021-0-US-03 Guidewire for Electrosurgical Tissue Laceration US National Stage 18/763,517 Pending
NHLBI E-144-2021-0-IL-01 TISSUE CUTTING SYSTEMS AND METHODS IL National Stage 314065 Pending
NIBIB E-054-2018-0-CN-01 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER CN DIV 202410872371.2 Pending
NIAAA E-190-2021-0-EP-01 Thiol-moeity Containing Cannabinoid Receptor Modulating Compounds EP National Stage 22847074.6 Pending
NIDDK E-051-2021-0-EP-02 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS EP DIV 24185703.6 Pending
NINDS E-119-2021-0-US-01 2,4-DIPHENYL-3,4-DIHYDROQUINAZOLINE DERIVATIVES AND RELATED COMPOUNDS AS D2 DOPAMINE RECEPTOR-SELECTIVE ANTAGONISTS US 63/666,563 Expired
NCATS E-057-2022-0-US-02 ESTRADIOL PRODRUGS AND METHODS OF USE THEREOF US National Stage 18/726,051 Pending
NCATS E-097-2023-0-PC-01 POTENT AND SELECTIVE DOPAMINE D3 ANTAGONISTS PCT PCT PCT/US2024/036149 Expired
NINDS E-186-2023-1-PC-01 Use of Iron Chelators for Treating Stuttering PCT PCT PCT/US2024/036062 Expired
NIAID E-297-2016-2-US-01 VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES US CON 18/758,660 Pending
NCI E-046-2022-0-JP-01 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER JP National Stage 2024-539628 Pending
NICHD E-184-2021-0-RU-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO RU National Stage 2024118060 Pending
NIAID E-080-2013-0-US-02 ATTENUATION OF HUMAN RESPIRATORY SYNCYTIAL VIRUS BY GENOME SCALE CODON-PAIR DEOPTIMIZATION US CON 18/756,709 Pending
NHGRI E-034-2022-0-EP-01 IMPROVED GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA EP National Stage 22856962.0 Pending
NCI E-282-2016-2-SG-03 Methods For Pre-conditioning Patients For Cell Therapy SG DIV 10202401902S Pending
NIAID E-208-2023-0-RU-01 HUMAN METAPNEUMOVIRUS VIRAL VECTOR-BASED VACCINES RU National Stage 2024117773 Pending
NIAID E-208-2023-0-NZ-01 HUMAN METAPNEUMOVIRUS VIRAL VECTOR-BASED VACCINES NZ National Stage 812509 Pending
NCI E-150-2017-2-SG-03 Diagnostic Methods For T Cell Therapy SG DIV 10202401903X Pending